MedTrace Logo

Carboplatin Plus Etoposide With or Without MPDL3280A in Untreated Extensive Stage Small Cell Lung Cancer

NCT02748889 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2018-07-02

Study results available
· View outcomes & findings →

Summary

This is an open-label study with two parts, a Phase I study and a randomized Phase II study. This study will be conducted at approximately ten sites in the United States. Approximately 178 patients will be enrolled in this trial.

Conditions

  • Small Cell Lung Cancer ( SCLC )

Interventions

DRUG

Carboplatin

Standard chemotherapy

DRUG

Etoposide

Standard chemotherapy

BIOLOGICAL

MPDL3280A

Experimental biologic

Sponsors & Collaborators

Principal Investigators

  • Giuseppe ( Beppe) Giaccone, Md,PhD · Georgetown Lombardi Comprehensive Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-31
Primary Completion
2017-05-09
Completion
2017-05-09

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02748889 on ClinicalTrials.gov